Nanomedicines in the treatment of acromegaly: focus on pegvisomant. (Q36920317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

2 references

30 June 2021

Nanomedicines in the treatment of acromegaly: focus on pegvisomant (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

20 November 2019

1 reference

20 November 2019

1 reference

30 June 2021

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2

Nienke R Biermasz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1

Ferdinand Roelfsema

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

4

Johannes Romijn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

English

0 references

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Nanomedicine

4 January 2020

published in

8 references

14 February 2019

13 March 2019

24 March 2019

25 April 2019

17 November 2019

20 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

30 June 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

385-398

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice

4 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Treatment strategies for acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Model for growth hormone receptor activation based on subunit rotation within a receptor dimer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Ubiquitin system-dependent regulation of growth hormone receptor signal transduction.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Systemic complications of acromegaly: epidemiology, pathogenesis, and management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Current concepts in the biochemical assessment of the patient with acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The pathophysiological consequences of somatostatin receptor internalization and resistance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Gamma knife radiosurgery in the management of patients with acromegaly: a review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Pegvisomant: structure and function

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The ubiquitin-proteasome pathway regulates the availability of the GH receptor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Pegylation: a novel process for modifying pharmacokinetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The somatomedin hypothesis: 2001.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Intracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GH.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/insulin-like growth factor system in adult mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Criteria for cure of acromegaly: a consensus statement

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The human growth hormone antagonist B2036 does not interact with the prolactin receptor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Affinity maturation of human growth hormone by monovalent phage display

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The crystal structure of affinity-matured human growth hormone at 2 A resolution

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Ascertainment and natural history of treated acromegaly in Northern Ireland

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Structural design and molecular evolution of a cytokine receptor superfamily

29 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

29 September 2017

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Mutations in the third alpha-helix of bovine growth hormone dramatically affect its intracellular distribution in vitro and growth enhancement in transgenic mice

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Growth Hormone Heterogeneity: Genes, Isohormones, Variants, and Binding Proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Treatment of acromegaly with dopamine agonists

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Signaling via JAK tyrosine kinases: growth hormone receptor as a model system

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

In vitro and in vivo studies of antagonistic effects of human growth hormone analogs.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Epidemiology of acromegaly in the Newcastle region

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

27 June 2018

Mortality in acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Body composition in acromegaly.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Rational design of potent antagonists to the human growth hormone receptor

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Regulation of growth-hormone-receptor gene expression by growth hormone and pegvisomant in human mesangial cells

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Dimerization and signal transduction of the growth hormone receptor

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Growth hormone receptor antagonist improves insulin resistance in acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

High-protein induced renal enlargement is growth hormone independent

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Effects of a growth hormone receptor antagonist on bone markers in acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatil

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Cabergoline in the treatment of acromegaly: a study in 64 patients.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

A low starting dose of genotropin in growth hormone-deficient adults

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Long-acting growth hormones produced by conjugation with polyethylene glycol.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Evidence for generation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptor

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2676637

Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984

4 September 2018

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Role of radiotherapy in the management of acromegaly

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Diagnosis of growth-hormone deficiency in adults

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Surgical outcome after repeated transsphenoidal surgery in acromegaly

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed Meal

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Activation of the growth hormone receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Altered neuroregulation of GH secretion in viscerally obese premenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Crystals of the complex between human growth hormone and the extracellular domain of its receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Crystals of human growth hormone-receptor complexes. Extracellular domains of the growth hormone and prolactin receptors and a hormone mutant designed to prevent receptor dimerization

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Radiotherapy in acromegaly: a protagonists viewpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FNANO.2006.1.4.385

Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys

1 reference

12 December 2020

Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly

1 reference

12 December 2020

Ten-year follow-up results of transsphenoidal microsurgery in acromegaly

1 reference

12 December 2020

Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer

1 reference

12 December 2020

Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action

1 reference

12 December 2020

Acromegaly. Clinical and biochemical features in 500 patients

1 reference

12 December 2020

Growth hormone secretion in recently operated acromegalic patients

1 reference

12 December 2020

10.2147/NANO.2006.1.4.385

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722273%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

PubMed publication ID

17722273

1 reference